A novel therapy for myasthenia gravis by reducing the endocytosis of acetylcholine receptors.
Kuncl
R W
RW
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Wittstein
I
I
Adams
R N
RN
Wiggins
W W
WW
Avila
O
O
Pestronk
A
A
McIntosh
K
K
Lucas
D
D
DeSilva
S
S
Lehar
M
M
D000818:Animals; D015536:Down-Regulation / Q000187:drug effects; D004705:Endocytosis / Q000187:drug effects; D005260:Female; D007114:Immunization; D007116:Immunization, Passive; D051379:Mice; D009157:Myasthenia Gravis / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D011978:Receptors, Nicotinic / Q000378:metabolism*; D014372:Tubercidin / Q000494:pharmacology
D011978:Receptors, Nicotinic; C018258:3-deazaadenosine; D014372:Tubercidin